top of page

Tonix to discontinue development of TNX-102 SL for fibromyalgia

Tonix Pharmaceuticals said it will stop the development of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia following its failure in a phase 3 trial.

The company said it will continue developing the drug for posttraumatic stress disorder (PTSD).

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page